CN101007062B - 一种抗感染中药组合物 - Google Patents
一种抗感染中药组合物 Download PDFInfo
- Publication number
- CN101007062B CN101007062B CN2006101722320A CN200610172232A CN101007062B CN 101007062 B CN101007062 B CN 101007062B CN 2006101722320 A CN2006101722320 A CN 2006101722320A CN 200610172232 A CN200610172232 A CN 200610172232A CN 101007062 B CN101007062 B CN 101007062B
- Authority
- CN
- China
- Prior art keywords
- caulis fibraureae
- foliole banyan
- radix scutellariae
- extract
- foliole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims description 38
- 208000015181 infectious disease Diseases 0.000 title description 11
- 239000000284 extract Substances 0.000 claims abstract description 38
- 230000002924 anti-infective effect Effects 0.000 claims abstract description 15
- 240000003537 Ficus benghalensis Species 0.000 claims description 72
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 34
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 30
- 229960003321 baicalin Drugs 0.000 claims description 30
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 4
- -1 NaCl iodine salt Chemical class 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 5
- 239000000470 constituent Substances 0.000 abstract 5
- 241001111214 Fibraurea Species 0.000 abstract 2
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 23
- 238000005303 weighing Methods 0.000 description 22
- RLQYRXCUPVKSAW-UHFFFAOYSA-M 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=C1 RLQYRXCUPVKSAW-UHFFFAOYSA-M 0.000 description 21
- RIDQRIPSFYHEGL-UHFFFAOYSA-N fibrauretin Natural products CC12CC=C3C(=O)OC(CC3(C)C1C(=O)C=CC2=O)c4cocc4 RIDQRIPSFYHEGL-UHFFFAOYSA-N 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010018691 Granuloma Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000725643 Respiratory syncytial virus Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000000954 anitussive effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 206010033971 Paratyphoid fever Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 3
- 229960005475 antiinfective agent Drugs 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 206010048245 Yellow skin Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000009254 shuang-huang-lian Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229940100050 virazole Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Abstract
Description
实验组别 | 正常对照 | 病毒对照 | 病毒唑对照 | 本发明组 | 黄藤提取物组 | 黄芩苷组 | 小叶榕浸膏组 |
给药剂量(mg/kg) | - | - | 10 | 800 | 800 | 800 | 800 |
对流感病毒FM1的保护率(%) | 100 | 10 | 100 | 100* | 50** | 85** | 20** |
对副流感病毒的保护率(%) | 100 | 0 | 90* | 100* | 60** | 90** | 45** |
分组 | 剂量(mg/kg) | 空斑单位(PFV/g102)(±SD) | 抑剂率(%) |
正常对照组病毒唑组RSV对照本发明组黄芩苷组黄藤提取物组小叶榕浸膏组 | -10-800800800800 | -0**42.8±2.210**12.5±1.43**19.4±1.6427.6±1.52** | -100010070.851.435.5 |
组别 | 剂量(mg/kg) | 肿胀度(mg) | 抑制率(%) |
空白对照阿斯匹林本发明组(低剂量) | -200200 | 14.7±4.26.9±3.8**10.1±2.7* | -53.131.3 |
本发明组(中剂量)本发明组(高剂量)黄藤提取物组黄芩苷组小叶榕浸膏组 | 400800800800800 | 8.9±3.2**8.2±3.4**9.0±2.4**8.7±2.9**9.4±3.1** | 39.544.238.840.836.1 |
组别 | 剂量(g/kg) | 肉芽肿重(mg100g体重) | 抑制率(%) |
空白对照阿斯匹林本发明组(低剂量)本发明组(中剂量)本发明组(高剂量)黄藤提取物组黄芩苷组小叶榕浸膏组 | -0.10.10.20.40.40.40.4 | 0.403±0.0610.257±0.051**0.352±0.083*0.309±0.066**0.272±0.059**0.301±0.046**0.286±0.037**0.348±0.041** | -36.212.723.332.525.329.013.7 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101722320A CN101007062B (zh) | 2005-12-31 | 2006-12-22 | 一种抗感染中药组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510136660 | 2005-12-31 | ||
CN200510136660.3 | 2005-12-31 | ||
CN2006101722320A CN101007062B (zh) | 2005-12-31 | 2006-12-22 | 一种抗感染中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101007062A CN101007062A (zh) | 2007-08-01 |
CN101007062B true CN101007062B (zh) | 2011-07-06 |
Family
ID=38695872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101722320A Expired - Fee Related CN101007062B (zh) | 2005-12-31 | 2006-12-22 | 一种抗感染中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101007062B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010040254A1 (zh) * | 2008-10-06 | 2010-04-15 | 大百汇生物科技(深圳)有限公司 | 黄芩黄酮在制备治疗肠道病毒感染药物的应用 |
CN102949456B (zh) * | 2011-08-30 | 2015-01-21 | 江守训 | 小叶榕萃取物的制备方法及促进伤口愈合的药物或伤口包扎物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1602886A (zh) * | 2003-09-29 | 2005-04-06 | 成都三明药物研究所 | 一种药物组合物及其用途 |
CN1660316A (zh) * | 2004-12-30 | 2005-08-31 | 北京正大绿洲医药科技有限公司 | 一种用于治疗支气管炎的滴丸制剂及其制备方法 |
-
2006
- 2006-12-22 CN CN2006101722320A patent/CN101007062B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1602886A (zh) * | 2003-09-29 | 2005-04-06 | 成都三明药物研究所 | 一种药物组合物及其用途 |
CN1660316A (zh) * | 2004-12-30 | 2005-08-31 | 北京正大绿洲医药科技有限公司 | 一种用于治疗支气管炎的滴丸制剂及其制备方法 |
Non-Patent Citations (4)
Title |
---|
中华人民共和国卫生部药典委员会.卫生部颁药品标准 中药成方制剂 第十四册.1997,108. * |
中华人民共和国卫生部药典委员会.卫生部颁药品标准中药成方制剂 第十四册.1997,108. |
叶荣科等.小叶榕树叶总黄酮水提醇沉工艺研究.广东药学院学报19 4.2003,19(4),330-331. |
叶荣科等.小叶榕树叶总黄酮水提醇沉工艺研究.广东药学院学报19 4.2003,19(4),330-331. * |
Also Published As
Publication number | Publication date |
---|---|
CN101007062A (zh) | 2007-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1698750A (zh) | 一种治疗咽炎的中药 | |
CN101085050A (zh) | 清热解毒制剂药物及其制备方法 | |
CN104013846A (zh) | 一种治疗口腔溃疡的中药组合物及其应用 | |
CN104107216A (zh) | 一种中药复方制剂及其制备方法和应用 | |
CN101007062B (zh) | 一种抗感染中药组合物 | |
CN103211901A (zh) | 一种清肺消炎药物及其制备方法 | |
CN101406629A (zh) | 一种用于治疗牙龈肿痛的口含片及其制备方法 | |
CN103463217B (zh) | 一种治疗肠炎痢疾的提取物、含其制剂及其制备方法和应用 | |
CN1895606A (zh) | 清热解毒、化痰止咳的中药制剂及其制备方法 | |
CN1943729A (zh) | 一种治疗外感发热中药组合物及其制备方法 | |
CN102429979A (zh) | 一种治疗感冒的中药组合物及其制备方法 | |
CN101032558B (zh) | 一种抗菌消炎的中药组合物 | |
CN111588748A (zh) | 一种治疗支气管炎的百里香精油软胶囊及其疗法 | |
CN101797263B (zh) | 一种抗菌消炎的中药组合物 | |
CN1840112A (zh) | 复方西羚解毒胶囊制剂及其制备方法 | |
CN104258020A (zh) | 一种治疗肺炎的中药组合物 | |
CN101721437B (zh) | 用于治疗慢性咽炎的药物组合物的制备方法 | |
CN103156988A (zh) | 一种用于清热利咽解毒止痛的分散片及其制备方法 | |
CN113425767B (zh) | 一种治疗肺炎的中药组合物 | |
CN103977313B (zh) | 一种利湿止痒丸及其制备方法 | |
CN102429982A (zh) | 一种治疗感冒的中药颗粒剂及其制备方法 | |
CN101810675A (zh) | 一种治疗咽炎的药物 | |
CN1660332A (zh) | 双黄连滴心丸制剂及其制备方法 | |
CN101683424A (zh) | 一种中药组合物在制备治疗扁桃体炎药物中的应用 | |
CN101322770A (zh) | 一种抗感染的复方穿心莲制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Yang Jing Document name: Notification that Application Deemed to be Withdrawn |
|
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Zhihong Inventor after: Bo Zhenjun Inventor after: Yang Jing Inventor before: Zhu Zhihong |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHU ZHIHONG TO: ZHU ZHIHONG BU ZHENJUN YANG JING |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN JIUDIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHU ZHIHONG Effective date: 20121226 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20121226 Address after: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee after: Hunan Jiudian Pharmaceutical Co., Ltd. Address before: 410005, Hunan province Changsha Furong Road section 368, BOBO world city 24 building Patentee before: Zhu Zhihong |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee after: HUNAN JIUDIAN PHARMACEUTICAL CO., LTD. Address before: 410005, Hunan, Changsha province Furong Road, No. 368 BOBO world city CTA wealth center, 24 floor Patentee before: Hunan Jiudian Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110706 Termination date: 20161222 |
|
CF01 | Termination of patent right due to non-payment of annual fee |